Um novo estudo com mais de 400 mil mulheres nos EUA revela que a Síndrome Ovariana Metabólica Poliendócrina (SOMP) aumenta em 4,4 vezes o risco de eventos cardiovasculares graves, independentemente de outros fatores de risco. Especialistas reforçam a urgência de monitoramento cardíaco precoce desde o diagnóstico.
Pesquisa publicada na "The Lancet" analisou dez "add-ons" de reprodução assistida e concluiu que apenas três mostraram algum benefício limitado. Para os demais, não houve efeito ou a qualidade dos dados foi baixa, gerando incerteza.
A menopausa é vista de forma mais individualizada, com foco na qualidade de vida. A terapia hormonal, antes vista como vilã, é reavaliada, mas desinformação sobre rejuvenescimento prolifera nas redes sociais.
Sun Pharma, India's largest pharma company, has acquired US-listed Organon & Co for $11.8 billion (Rs 98,000 crore) in an all-cash transaction — the biggest-ever overseas pharma deal by an Indian company. Sun Pharma will pay $14 per share, a 24% premium to Organon's closing price. The acquisition adds over 140 high-growth markets including China, and portfolio of women's health, biosimilars, and legacy brands. Once completed, it will double Sun Pharma's revenue to $12.4 billion and EBITDA to $3.7 billion, ranking it among top 25 global pharmaceutical companies.
Indian pharmaceutical giant Sun Pharma is set to acquire US-based Organon & Co. for $11.75 billion in an all-cash deal. This landmark acquisition, one of India's largest overseas ventures, will propel Sun Pharma into the top 25 global pharma companies. The move significantly bolsters its presence in women's health and biosimilars, expanding its global reach across 150 countries.
This week's discussion focuses on how AI can enhance healthcare by improving professional workflows, enabling earlier disease detection, and transforming personal health management. It also features an interview on accessible female health tech and a positive story from the internet's darker corners.
